Drug

Arsenic trioxide (Trisenox)

An injectable drug that treats acute promyelocytic leukaemia together with tretinoin

Updated: 27 October 20261 min read3 references
Generic name
Arsenic trioxide
Brand names
Trisenox
Drug class
Arsenical (inducer of differentiation and apoptosis)
Route
Intravenous infusion
Show content for:

Key points

  • Arsenic trioxide with tretinoin cures most patients with APL without chemotherapy [2]; the European guideline considers it the standard treatment for low-‎ and intermediate-risk APL [3].
  • It is given into a vein every day; induction until remission, then 4 consolidation cycles [1].
  • The ECG and blood salts (potassium and magnesium) are checked regularly [1].

What is this drug and how does it work?

For patients

Arsenic trioxide breaks down the faulty protein that keeps APL cells immature and so gets rid of these cells [1].

For physiciansSpecialist notes
For physicians

Degradation of PML-RARA through its PML moiety, with induction of partial differentiation and apoptosis [1].

Which cancers is it used for?

For patients
What is this drug for?
  • Newly diagnosed low-risk acute promyelocytic leukaemia, with tretinoin [1, 2]
  • Relapsed or refractory APL [1]
For physiciansApproved uses and evidence
For physicians
Approved uses and evidence
DiseaseUseKey evidence
Newly diagnosed low-risk APLWith tretinoin [1]APL0406: 2-year event-free survival 97% vs 86% [2]
Relapsed APLInduction and consolidation [1]—

How it is taken and dosing

Show detailsHide

A daily infusion into a vein in hospital or a clinic, usually over 2 hours (up to 4 hours if there is a reaction) [1].

For physiciansStandard dosing (FDA label), 1 regimen
For physicians

Standard dosing (FDA label)

Arsenic trioxide

Newly diagnosed low-risk APL (with tretinoin)

Newly diagnosed low-risk APL (with tretinoin)

DrugDoseRouteSchedule
Induction
Arsenic trioxide0.15 mg/kgIVDaily until remission (maximum 60 days)
Consolidation: 4 cycles
Arsenic trioxide0.15 mg/kgIV5 days a week, weeks 1 to 4 of each 8-week cycle
Cycle length
Induction daily; consolidation every 8 weeks
Duration
1 induction course and 4 consolidation cycles

As per the label [1] and APL0406 [2].

Evidence: APL0406 (2013)

Doses follow the trial protocol, guideline or official drug label (source given in the notes of each regimen). Before prescribing, check blood counts, renal and hepatic function, drug interactions and the patient’s condition, and adjust the dose according to the drug label.

Side effects

For patients

The most common side effects: nausea, cough, tiredness, fever, headache, abdominal pain, vomiting, a racing heart, diarrhoea, low potassium and magnesium, high blood sugar and swelling [1].

For physiciansSpecialist notes
For physicians

Common adverse reactions (above 30%): nausea, cough, fatigue, pyrexia, headache, abdominal pain, vomiting, tachycardia, diarrhoea, dyspnoea, hypokalaemia, leucocytosis, hyperglycaemia, hypomagnesaemia, insomnia, dermatitis, oedema and QTc prolongation [1].

Serious side effects

For patients

Serious side effects: differentiation syndrome, dangerous heart rhythm changes, brain damage (encephalopathy, including Wernicke) and liver damage [1].

For physiciansSpecialist notes
For physicians
  • Boxed warning: differentiation syndrome and cardiac conduction abnormalities [1].
  • Baseline and weekly ECG; keep potassium and magnesium in the normal range; QTc above 500: hold (QTc) [1].
  • Wernicke encephalopathy: if suspected, hold and give IV thiamine [1].

When should I call my doctor?

  • Palpitations, fainting or dizziness
  • Fever, shortness of breath or weight gain
  • Confusion, or problems with vision or walking

Interactions, pregnancy and precautions

  • Other medicines: medicines that prolong the heart rhythm or lower potassium and magnesium (some diuretics, amphotericin) only with caution and under medical supervision [1].
  • Pregnancy: this drug may harm an unborn baby; use effective contraception during treatment and tell your doctor straight away if you become pregnant. Do not breastfeed during treatment [1].
For patients

Frequently asked questions

Isn't arsenic a poison?

At treatment doses and with monitoring, it is a highly effective drug for APL; regular ECGs and blood tests make it safer [1, 2].

Related cancer types

Treatment regimens (physicians)

References

3 references
Show all references, 1 with a study cardClose the reference list

Numbers in the text, such as [1], refer to these sources. Sources with a “Study card” button are summarised in the site’s evidence library.

  1. 1
    TRISENOX (ARSENIC TRIOXIDE) — Prescribing InformationCephalon, LLC · FDA label · 2026
    Source Back to text: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
  2. 2
    Retinoic acid and arsenic trioxide for acute promyelocytic leukemiaLo-Coco F, Avvisati G, Vignetti M, et al · N Engl J Med · 2013;369:111-21
    Study cardDOIPubMed Back to text: 1 2 3 4 5
  3. 3
    Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNetSanz MA, Fenaux P, Tallman MS, et al · Blood · 2019;133:1630-1643

This page is based on reputable scientific sources and was last updated on 27 October 2026. The content of this website is for educational and informational purposes only and does not replace consultation, diagnosis or treatment by a specialist physician. Consult your treating physician about any treatment decision.